CareDx (NASDAQ: CDNA) reported Q1 EPS of $0.00, $0.03 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $38.4 million versus the consensus estimate of $37.99 million.

“We are very pleased with our first quarter results, which reflect strong execution and the continued growth and penetration of our innovative and intelligent solutions for transplant patients and caregivers,” said Peter Maag, CareDx Chief Executive Officer. “Throughout this unprecedented time, our team has shown unrelenting dedication to transforming transplant care and ensuring that foundationally we remain strong and well-positioned for continuous growth.”

GUIDANCE:

Due to the continued uncertainties from the impact of COVID-19, CareDx withdrew its 2020 guidance on April 8, 2020.

For earnings history and earnings-related data on CareDx (CDNA) click here.